Affimed to Present at the Jefferies 2018 London Healthcare Conference

Press Release - November 8, 2018

Heidelberg, Germany, November 8, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK cells, macrophages and T cells), today announced that Dr. Adi Hoess, CEO, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14, 2018 at 8:40 am GMT in London.

A live webcast of the conference presentation can be accessed through the “Events” section on the “Investors & Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK cells, macrophages and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

Affimed Investor Contact:

Gregory Gin,
Head of Investor Relations
E-Mail: email hidden; JavaScript is required

Affimed Media Contact:

Anca Alexandru,
Head of Communications, EU IR
E-Mail: email hidden; JavaScript is required

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay